Breaking News Instant updates and real-time market news.

CVS

CVS Health

$63.38

-0.62 (-0.97%)

10:35
04/13/18
04/13
10:35
04/13/18
10:35

CVS Health names Marc-David Munk associate Chief Medical Officer

CVS Health announced that it has named Marc-David Munk, MD, MPH, MHCM, as the new Chief Medical Officer of MinuteClinic, the company's retail medical clinic subsidiary, and as Associate Chief Medical Officer of CVS Health. In his new role, Munk will lead and oversee MinuteClinic's patient care strategies with a focus on ensuring that MinuteClinic continues to provide high-quality clinical care to patients. In addition, Munk will help further develop innovative strategic programming and expanded health care services across the CVS Health enterprise. Munk was most recently the Chief Medical Officer of Iora Health.

CVS CVS Health
$63.38

-0.62 (-0.97%)

04/02/18
LEER
04/02/18
NO CHANGE
LEER
Possible Humana/Walmart deal transformational for U.S. seniors market, says Leerink
Leerink analyst Ana Gupte sees the possible Humana (HUM)-Walmart (WMT) deal as transformational for the U.S. Seniors market and estimates the deal value at close to $50B. The analyst also believes the deal helps Humana compete more effectively with UnitedHealth (UNH)/Optum and Aetna (AET)-CVS (CVS), while Walmart can also compete with Amazon (AMZN) that is eroding sales and likely eyeing an entry into the Prescription Rx market. Gupte expects the anti-trust scrutiny of three deals Aetna-CVS, Cigna (CI)-Express Scripts (ESRX) and Humana-Walmart by the DOJ will be more challenged under simultaneous review by the DOJ, though Walmart and Humana have the least anti-competitive issues. Humana-Walmart could catalyze a counter-offer for Cigna from Walgreens Boots Alliance (WBA) or even Amazon, or re-invigorate Walgreens-AmerisourceBergen (ABC) talks, she contends.
04/02/18
MSCO
04/02/18
NO CHANGE
MSCO
Equal Weight
Morgan Stanley says may make sense for Walmart to play bigger role in healthcare
Morgan Stanley analyst Simeon Gutman estimates Walmart (WMT) generates about $20B in pharmacy sales annually, which he believes makes it the third largest U.S. pharmacy provider behind CVS (CVS) and Walgreens (WBA). Following a report from The Wall Street Journal that the company and Humana (HUM) were in merger talks, and subsequent reports from Reuters and Bloomberg that the two may only be discussing a broader partnership instead of a buyout deal, Gutman said that consolidation of other retailers and healthcare providers could put Walmart at a disadvantage and he believes it may make sense for Walmart to play a larger role in healthcare. He maintains an Equal Weight rating on Walmart shares.
04/05/18
CHLM
04/05/18
NO CHANGE
Target $30
CHLM
Hold
CVS focusing on home dialysis positive for NxStage Medical, says Craig-Hallum
Craig-Hallum analyst Kevin Ellich notes that CVS Health (CVS) announced an initiative to improve patient outcomes for chronic kidney disease and dialysis. The analyst believes that a company of CVS Health's size and stature focusing on home dialysis and specifically home hemodialysis is a positive for NxStage Medical (NXTM) since it is the market leader with a huge head start. While there could be concerns about price competition if and when CVS Health is able to get a home hemodialysis device to market, NxStage Medical will have its next generation products to market, as well as a peritoneal dialysis machine, he contends, adding that he thinks the market opportunity will be much larger. Ellich reiterates a Hold rating and $30 price target on NxStage Medical's shares.
04/10/18
LEER
04/10/18
NO CHANGE
Target $85
LEER
Outperform
CVS drug trend report highlights value of PBM model, says Leerink
Leerink analyst David Larsen notes that CVS recently published its 2017 drug trend report, and reported good performance, posting total drug trend of +1.9%. In his view, this trend which is a five-year low, and the 0.2% reported drug price growth, is evidence that the PBM business model delivers significant value to clients. The analyst is generally positive on the PBM business model, and despite constant "noise" around transparency and drug costs, he believes the proof is in the trend. Larsen reiterates an Outperform rating and $85 price target on the shares.

TODAY'S FREE FLY STORIES

INXN

Interxion

$64.05

0.77 (1.22%)

07:21
07/17/18
07/17
07:21
07/17/18
07:21
Initiation
Interxion initiated  »

Interxion resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

07:20
07/17/18
07/17
07:20
07/17/18
07:20
General news
FX Update: The Dollar remained on a softening tack »

FX Update: The Dollar…

BAESY

BAE Systems

$0.00

(0.00%)

07:19
07/17/18
07/17
07:19
07/17/18
07:19
Periodicals
BAE Systems wants international partners for UK fighter project, Reuters says »

BAE Systems wants to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INAP

Internap

$11.31

-0.63 (-5.28%)

07:19
07/17/18
07/17
07:19
07/17/18
07:19
Initiation
Internap initiated  »

Internap resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

V

Visa

$138.45

-0.91 (-0.65%)

, MA

MasterCard

$204.05

-1.86 (-0.90%)

07:19
07/17/18
07/17
07:19
07/17/18
07:19
Recommendations
Visa, MasterCard analyst commentary  »

Visa price target raised…

V

Visa

$138.45

-0.91 (-0.65%)

MA

MasterCard

$204.05

-1.86 (-0.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 26

    Jul

FDC

First Data

$22.24

-0.06 (-0.27%)

07:19
07/17/18
07/17
07:19
07/17/18
07:19
Recommendations
First Data analyst commentary  »

First Data price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

EQIX

Equinix

07:17
07/17/18
07/17
07:17
07/17/18
07:17
Initiation
Equinix initiated  »

Equinix resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Aug

MA

MasterCard

$204.05

-1.86 (-0.90%)

07:17
07/17/18
07/17
07:17
07/17/18
07:17
Recommendations
MasterCard analyst commentary  »

MasterCard price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

AUTL

Autolus Therapeutics

$23.00

2.11 (10.10%)

07:16
07/17/18
07/17
07:16
07/17/18
07:16
Initiation
Autolus Therapeutics initiated  »

Autolus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVT

Avnet

07:15
07/17/18
07/17
07:15
07/17/18
07:15
Initiation
Avnet initiated  »

Avnet initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARW

Arrow Electronics

$77.09

-0.47 (-0.61%)

07:15
07/17/18
07/17
07:15
07/17/18
07:15
Initiation
Arrow Electronics initiated  »

Arrow Electronics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QURE

uniQure

$35.08

-4.41 (-11.17%)

, PFE

Pfizer

$37.39

-0.14 (-0.37%)

07:15
07/17/18
07/17
07:15
07/17/18
07:15
Recommendations
uniQure, Pfizer analyst commentary  »

uniQure pullback on…

QURE

uniQure

$35.08

-4.41 (-11.17%)

PFE

Pfizer

$37.39

-0.14 (-0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 10

    Sep

AMBA

Ambarella

$37.58

-0.32 (-0.84%)

07:14
07/17/18
07/17
07:14
07/17/18
07:14
Initiation
Ambarella initiated  »

Ambarella initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BF.B

Brown-Forman, also tag with BFA, BFB

$51.18

0.14 (0.27%)

, BFA

Brown-Forman, also tag with BF.A, BF.B

$0.00

(0.00%)

07:13
07/17/18
07/17
07:13
07/17/18
07:13
Upgrade
Brown-Forman, also tag with BFA, BFB, Brown-Forman, also tag with BF.A, BF.B, Brown-Forman, also tag with BF.A, BF.B rating change  »

Brown-Forman upgraded to…

BF.B

Brown-Forman, also tag with BFA, BFB

$51.18

0.14 (0.27%)

BFA

Brown-Forman, also tag with BF.A, BF.B

$0.00

(0.00%)

BFB

Brown-Forman, also tag with BF.A, BF.B

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$207.33

(0.00%)

07:13
07/17/18
07/17
07:13
07/17/18
07:13
Periodicals
Facebook uses 'shielded review' process for popular pages, The Guardian reports »

Leading far-right…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 25

    Jul

  • 18

    Sep

CHUY

Chuy's

07:11
07/17/18
07/17
07:11
07/17/18
07:11
Downgrade
Chuy's rating change  »

Chuy's downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

DLR

Digital Realty

$115.64

-0.66 (-0.57%)

07:11
07/17/18
07/17
07:11
07/17/18
07:11
Initiation
Digital Realty initiated  »

Digital Realty resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

NFLX

Netflix

$400.24

4.32 (1.09%)

07:10
07/17/18
07/17
07:10
07/17/18
07:10
Recommendations
Netflix analyst commentary  »

Netflix valuation remains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLMN

Bloomin' Brands

$20.72

-0.36 (-1.71%)

07:09
07/17/18
07/17
07:09
07/17/18
07:09
Upgrade
Bloomin' Brands rating change  »

Bloomin' Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

CANF

Can-Fite BioPharma

$1.23

-0.04 (-3.15%)

07:09
07/17/18
07/17
07:09
07/17/18
07:09
Hot Stocks
Can-Fite BioPharma receives patent from China, Australia for sexual dysfunction »

Can-Fite BioPharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COR

CoreSite Realty

$112.91

-0.86 (-0.76%)

07:09
07/17/18
07/17
07:09
07/17/18
07:09
Initiation
CoreSite Realty initiated  »

CoreSite Realty resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

INNT

Innovate Biopharmaceuticals

$8.07

-15.65 (-65.98%)

07:08
07/17/18
07/17
07:08
07/17/18
07:08
Initiation
Innovate Biopharmaceuticals initiated  »

Innovate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

AST

Asterias

$1.70

-0.05 (-2.86%)

07:08
07/17/18
07/17
07:08
07/17/18
07:08
Hot Stocks
Asterias provides six month data readout for AST-OPC1 Phase 1/2a clinical trial »

Asterias Biotherapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSU

Nevsun Resources

$3.21

-0.06 (-1.84%)

07:07
07/17/18
07/17
07:07
07/17/18
07:07
Hot Stocks
Nevsun Resources advises that no formal offer has yet been made by Lundin Mining »

Nevsun Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

CONE

CyrusOne

$61.71

0.08 (0.13%)

07:06
07/17/18
07/17
07:06
07/17/18
07:06
Initiation
CyrusOne initiated  »

CyrusOne resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 09

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.